Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.45, in-line with the analyst estimate of $0.45. Revenue for the quarter came in at $282.2 million versus the consensus estimate of $283.7 million.

• The company is tightening full-year 2017 revenue guidance to a new range of $1.125 billion to $1.140 billion, reflecting changes in foreign currency expectations and overperformance in Derma Sciences. The company is also revising 2017 full-year organic sales growth to a new range of 6.0% to 7.0% from its previous guidance of 7.0% to 8.5%, which reflects expectations for lower organic sales growth from Dural Repair;
• The company is maintaining previously issued 2017 full-year GAAP and adjusted earnings per share guidance;

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.